Real-World Analysis Evaluates Inpatient Vs Outpatient CAR T-Cell Therapy Administration in MCL and F
As CAR T-cell therapies have gained approvals in relapsed/refractory mantle cell lymphoma (MCL) and follicular lymphoma (FL) patient populations, there is continued interest in the optimal administration of this treatment option. CAR T-cell therapy is typically administered in the hospital setting, but as the therapy continues to become more widely used in clinical practice, there […]
